Rocket Pharmaceuticals: President Patel to depart, 30% workforce cut, Q2 net loss $68.9M

ROCKET PHARMACEUTICALS, INC.

Dr. Kinnari Patel to leave as President and Head of R&D effective Dec 31, 2025; steps down Aug 8.
Workforce reduction of ~30% and cash burn cut ~25% as part of strategic restructuring.
Q2 net loss $68.9M ($0.62/share); cash $271.5M; expects runway into Q2 2027.
Clinical hold on RP-A501 Danon disease trial ongoing after patient death; engaging with FDA.
Chris Stevens appointed COO in July; former Spark Therapeutics executive.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.